ClinicalTrials.Veeva

Menu

Enhancing Health Literacy Through AI-Powered Chatbot: a Randomized Controlled Trial

The University of Hong Kong (HKU) logo

The University of Hong Kong (HKU)

Status

Not yet enrolling

Conditions

Healthy

Treatments

Behavioral: AI-based chatbot
Behavioral: Leaflet

Study type

Interventional

Funder types

Other

Identifiers

NCT06702423
UW231392

Details and patient eligibility

About

The goal of this study is to learn if an innovative digital artificial intelligence (AI)-based communication tool works to enhance health literacy among Japanese caregivers regarding Human Papillomavirus (HPV) vaccination.

Participants will:

  • Answer a pre-intervention survey, get information regarding HPV vaccination from an AI-based chatbot or leaflet, and answer a post-intervention survey.
  • Continue interacting with the chatbot or leaflet for two weeks.
  • Answer a follow-up survey.

Full description

This study will evaluate the efficacy and feasibility of an AI-driven chatbot in enhancing caregivers' health literacy about HPV vaccination and examines its impact on informed decision-making concerning their daughters' vaccination through a randomized controlled trial (RCT). To achieve this, the study will undertake the following interconnected activities:

  1. Randomized Controlled Trial Participants will be randomly assigned to either the control or intervention group. Those in the control group will spend 5-10 minutes reading a publicly accessible HPV vaccination leaflet prepared by the MHLW, serving as the standard of care. Conversely, participants in the intervention group will be invited to interact with the chatbot for 5-10 minutes, posing inquiries (n>10) about HPV vaccination policies and related topics in Japan. Pre- and post-intervention assessments, as detailed below, will be administered to evaluate the chatbot's effectiveness and feasibility to counter HPV vaccine misinformation and support caregivers' vaccination decision-making processes.
  2. Pre- and post-intervention assessments Following informed consent and enrollment, participants will complete a pre-intervention survey to establish baseline data. Post-intervention survey will be introduced at two touchpoints: the first is directly after spending time with either a leaflet (control) or a chatbot (intervention), and the second is two weeks after the first touchpoint.

The surveys are designed to assess the chatbot's effectiveness in enhancing caregivers' digital health literacy about HPV vaccination and facilitating informed vaccine decision-making.

Enrollment

844 estimated patients

Sex

Female

Ages

20+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • A nationally representative sample of female caregivers with daughters aged 12-18 who have not received any HPV vaccine.
  • Those who have access to a smartphone or computer with internet connectivity to interact with experiment materials (chatbot or online leaflet).
  • Those who provide informed consent and agree to participate in the study.

Exclusion criteria

  • Those who need help reading through the participant information sheet, providing consent online, accessing experiment materials (chatbot or online leaflet), or answering surveys will be excluded. This may include people who do not have access to an online environment or people with severe cognitive impairments who cannot interact with the experiment materials. Also, those who have participated or are participating in similar studies regarding vaccination or experiments that utilize chatbots will be excluded.

Trial design

Primary purpose

Health Services Research

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

844 participants in 2 patient groups

AI-based chatbot
Experimental group
Description:
A chatbot that was developed using information related to HPV vaccines from authoritative sources such as the Japanese Ministry of Health, Labour, and Welfare, World Health Organization, Centers for Disease Control and Prevention, and other reputable public health organizations and validated survey questions from published research.
Treatment:
Behavioral: AI-based chatbot
Leaflet
Active Comparator group
Description:
A leaflet which is a publicly accessible HPV vaccination document prepared by the Ministry of Health, Labour, and Welfare.
Treatment:
Behavioral: Leaflet

Trial contacts and locations

1

Loading...

Central trial contact

Kana Kobayashi, MSPH; Leesa Lin, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems